Guardant Health, Inc. (NASDAQ:GH) Receives $53.29 Consensus PT from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH - Get Free Report) have been given a consensus recommendation of "Buy" by the twenty-one ratings firms that are presently covering the stock, Marketbeat.com reports. Twenty research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $53.29.

A number of research firms have weighed in on GH. Barclays upped their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, May 1st. Morgan Stanley raised their price objective on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Stephens reiterated an "overweight" rating and set a $55.00 target price on shares of Guardant Health in a research note on Wednesday, March 26th. Piper Sandler reissued an "overweight" rating and set a $60.00 price target (up previously from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. Finally, UBS Group upped their price target on shares of Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a report on Thursday, May 1st.

Insider Buying and Selling at Guardant Health

In other news, CEO Amirali Talasaz sold 77,853 shares of Guardant Health stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $50.09, for a total transaction of $3,899,656.77. Following the sale, the chief executive officer now owns 2,069,456 shares of the company's stock, valued at approximately $103,659,051.04. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 226,516 shares of company stock worth $11,226,549. 6.10% of the stock is owned by insiders.

Institutional Trading of Guardant Health

Several large investors have recently added to or reduced their stakes in GH. Vanguard Group Inc. grew its stake in shares of Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after purchasing an additional 350,606 shares in the last quarter. Deep Track Capital LP lifted its holdings in Guardant Health by 7.0% in the fourth quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock worth $196,118,000 after purchasing an additional 419,006 shares during the period. Invesco Ltd. lifted its holdings in Guardant Health by 100.9% in the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company's stock worth $119,053,000 after purchasing an additional 1,403,670 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Guardant Health by 6.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company's stock valued at $118,302,000 after buying an additional 164,263 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in Guardant Health by 96.7% during the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock valued at $70,742,000 after buying an additional 1,138,300 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Price Performance

Guardant Health stock traded down $0.01 during midday trading on Monday, hitting $49.02. 1,250,401 shares of the company were exchanged, compared to its average volume of 2,126,758. Guardant Health has a fifty-two week low of $20.14 and a fifty-two week high of $52.92. The company's fifty day moving average price is $43.39 and its 200-day moving average price is $41.36. The company has a market cap of $6.07 billion, a PE ratio of -13.77 and a beta of 1.37.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. The business had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business's revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.46) earnings per share. On average, analysts expect that Guardant Health will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.